ReviewFrontiers in endocrinology2020
Glucose Intolerance on Phaeochromocytoma and Paraganglioma-The Current Understanding and Clinical Perspectives.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Silent pheochromocytoma presenting as refractory hyperglycemia without classic adrenergic symptoms.JCEM case reports · 2026Article
- Pheochromocytoma presenting with hyperosmolar hyperglycemic state and transient stroke-like deficits.JCEM case reports · 2026Article
- Pheochromocytoma unmasked by rapid deterioration of previously stable type 2 diabetes.JCEM case reports · 2026Article
- Article
- Differences in management and outcomes between pheochromocytomas and sympathetic paragangliomas.Frontiers in endocrinology · 2026Article
- Pheochromocytoma Across the Perioperative Course: Current Concepts and Clinical Management.Anesthesiology research and practice · 2026Review
- Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism.Journal of endocrinological investigation · 2025Review
- Retrospective analysis of robotic versus laparoscopic surgery in the treatment of giant pheochromocytoma and paraganglioma.Journal of robotic surgery · 2025Article
- Case report: From metabolic instability to remission: a case of pheochromocytoma presenting as atypical diabetes.Frontiers in endocrinology · 2025Article
- Editorial: Recent advances in secondary diabetes and glucose intolerance.Frontiers in endocrinology · 2025Article
- The frequency of postoperative hypoglycemia after pheochromocytoma surgery is decreasing.World journal of surgery · 2024Article
- Review
- Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma.Endocrine oncology (Bristol, England) · 2023Article
- UPLC-G2Si-HDMS Untargeted Metabolomics for Identification of Yunnan Baiyao's Metabolic Target in Promoting Blood Circulation and Removing Blood Stasis.Molecules (Basel, Switzerland) · 2022Article
- Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.Frontiers in endocrinology · 2022Review
- Circulating GLP-1 Levels in Patients with Pheochromocytoma/Paraganglioma.International journal of endocrinology · 2022Article
- Case Report: Malignant Pheochromocytoma Without Hypertension Accompanied by Increment of Serum VEGF Level and Catecholamine Cardiomyopathy.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Half of the patients with phaeochromocytoma have glucose intolerance which could be life-threatening as well as causing postoperative hypoglycemia. Glucose intolerance is due to impaired insulin secretion and/or increased insulin resistance. Impaired insulin secretion is caused by stimulating adrenergic α2 receptors of pancreatic β-cells and increased insulin resistance is caused by stimulating adrenergic α1 and β3 receptors in adipocytes, α1 and β2 receptors of pancreatic α-cells and skeletal muscle. Furthermore, different affinities to respective adrenergic receptors exist between epinephrine and norepinephrine. Clinical studies revealed patients with phaeochromocytoma had impaired insulin secretion as well as increased insulin resistance. Furthermore, excess of epinephrine could affect glucose intolerance mainly by impaired insulin secretion and excess of norepinephrine could affect glucose intolerance mainly by increased insulin resistance. Glucose intolerance on paraganglioma could be caused by increased insulin resistance mainly considering paraganglioma produces more norepinephrine than epinephrine. To conclude, the difference of actions between excess of epinephrine and norepinephrine could lead to improve understanding and management of glucose intolerance on phaeochromocytoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.